In 52 patients with PAH or CTEPH on background vasodilator therapy, 12 weeks of dapagliflozin did not improve peak VO2 vs placebo (adjusted mean difference −0.67 mL/kg/min; p=0.187; 51 analysed), nor haemodynamics or 6MWD.
RCTn = 52
Ersbøll et al. Dapagliflozin in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: The DAPAH randomized controlled trial